Carta científico-clínica
Tratamiento con aprepitant del prurito refractario secundario a linfoma cutáneo de células T
Aprepitant in the Treatment of Refractory Pruritus Secondary to Cutaneous T-Cell Lymphoma
Leído
12359
Vecesse ha leído el artículo
3217
Total PDF
9142
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 6 | 46 | 5 | 51 |
| 2025 5 | 199 | 42 | 241 |
| 2025 4 | 194 | 29 | 223 |
| 2025 3 | 208 | 29 | 237 |
| 2025 2 | 186 | 29 | 215 |
| 2025 1 | 174 | 29 | 203 |
| 2024 12 | 195 | 41 | 236 |
| 2024 11 | 172 | 53 | 225 |
| 2024 10 | 163 | 42 | 205 |
| 2024 9 | 176 | 21 | 197 |
| 2024 8 | 175 | 41 | 216 |
| 2024 7 | 177 | 28 | 205 |
| 2024 6 | 216 | 59 | 275 |
| 2024 5 | 171 | 47 | 218 |
| 2024 4 | 158 | 27 | 185 |
| 2024 3 | 160 | 28 | 188 |
| 2024 2 | 162 | 30 | 192 |
| 2024 1 | 176 | 35 | 211 |
| 2023 12 | 151 | 19 | 170 |
| 2023 11 | 151 | 46 | 197 |
| 2023 10 | 140 | 21 | 161 |
| 2023 9 | 137 | 30 | 167 |
| 2023 8 | 117 | 27 | 144 |
| 2023 7 | 136 | 49 | 185 |
| 2023 6 | 121 | 22 | 143 |
| 2023 5 | 156 | 28 | 184 |
| 2023 4 | 128 | 21 | 149 |
| 2023 3 | 108 | 36 | 144 |
| 2023 2 | 143 | 18 | 161 |
| 2022 1 | 87 | 40 | 127 |
| 2022 12 | 105 | 33 | 138 |
| 2022 11 | 136 | 36 | 172 |
| 2022 10 | 108 | 43 | 151 |
| 2022 9 | 137 | 39 | 176 |
| 2022 8 | 139 | 57 | 196 |
| 2022 7 | 100 | 63 | 163 |
| 2022 6 | 73 | 34 | 107 |
| 2022 5 | 85 | 45 | 130 |
| 2022 4 | 91 | 40 | 131 |
| 2022 3 | 76 | 59 | 135 |
| 2022 2 | 58 | 27 | 85 |
| 2021 1 | 81 | 46 | 127 |
| 2021 12 | 56 | 42 | 98 |
| 2021 11 | 66 | 48 | 114 |
| 2021 10 | 93 | 62 | 155 |
| 2021 9 | 88 | 56 | 144 |
| 2021 8 | 62 | 49 | 111 |
| 2021 7 | 70 | 49 | 119 |
| 2021 6 | 85 | 54 | 139 |
| 2021 5 | 114 | 38 | 152 |
| 2021 4 | 163 | 68 | 231 |
| 2021 3 | 106 | 29 | 135 |
| 2021 2 | 87 | 35 | 122 |
| 2020 1 | 74 | 28 | 102 |
| 2020 12 | 51 | 31 | 82 |
| 2020 11 | 65 | 25 | 90 |
| 2020 10 | 71 | 24 | 95 |
| 2020 9 | 61 | 11 | 72 |
| 2020 8 | 44 | 23 | 67 |
| 2020 7 | 41 | 17 | 58 |
| 2020 6 | 47 | 23 | 70 |
| 2020 5 | 41 | 23 | 64 |
| 2020 4 | 38 | 26 | 64 |
| 2020 3 | 42 | 24 | 66 |
| 2020 2 | 6 | 9 | 15 |
| 2020 1 | 5 | 5 | 10 |
| 2019 12 | 8 | 8 | 16 |
| 2019 11 | 10 | 6 | 16 |
| 2019 10 | 0 | 7 | 7 |
| 2019 9 | 10 | 5 | 15 |
| 2019 8 | 5 | 2 | 7 |
| 2019 7 | 4 | 7 | 11 |
| 2019 6 | 7 | 1 | 8 |
| 2019 5 | 2 | 19 | 21 |
| 2019 4 | 26 | 28 | 54 |
| 2019 3 | 6 | 19 | 25 |
| 2019 2 | 4 | 17 | 21 |
| 2019 1 | 2 | 14 | 16 |
| 2018 12 | 2 | 7 | 9 |
| 2018 11 | 16 | 15 | 31 |
| 2018 10 | 24 | 13 | 37 |
| 2018 9 | 5 | 5 | 10 |
| 2018 8 | 1 | 11 | 12 |
| 2018 7 | 1 | 15 | 16 |
| 2018 6 | 0 | 10 | 10 |
| 2018 5 | 0 | 12 | 12 |
| 2018 4 | 1 | 1 | 2 |
| 2018 3 | 4 | 6 | 10 |
| 2018 2 | 64 | 10 | 74 |
| 2018 1 | 65 | 18 | 83 |
| 2017 12 | 83 | 18 | 101 |
| 2017 11 | 42 | 16 | 58 |
| 2017 10 | 64 | 17 | 81 |
| 2017 9 | 36 | 37 | 73 |
| 2017 8 | 38 | 24 | 62 |
| 2017 7 | 54 | 22 | 76 |
| 2017 6 | 44 | 41 | 85 |
| 2017 5 | 43 | 25 | 68 |
| 2017 4 | 42 | 23 | 65 |
| 2017 3 | 42 | 44 | 86 |
| 2017 2 | 97 | 36 | 133 |
| 2016 1 | 35 | 32 | 67 |
| 2016 12 | 52 | 12 | 64 |
| 2016 11 | 53 | 34 | 87 |
| 2016 10 | 67 | 45 | 112 |
| 2016 9 | 120 | 27 | 147 |
| 2016 8 | 1 | 26 | 27 |
| 2016 7 | 12 | 4 | 16 |
| 2016 6 | 15 | 2 | 17 |
| 2016 5 | 7 | 4 | 11 |
| 2016 4 | 10 | 4 | 14 |
| 2016 3 | 9 | 30 | 39 |
| 2016 2 | 14 | 2 | 16 |
| 2015 1 | 8 | 2 | 10 |
| 2015 12 | 14 | 7 | 21 |
| 2015 11 | 9 | 1 | 10 |
| 2015 10 | 13 | 9 | 22 |
| 2015 9 | 12 | 2 | 14 |
| 2015 8 | 12 | 4 | 16 |
| 2015 7 | 68 | 12 | 80 |
| 2015 6 | 45 | 14 | 59 |
| 2015 5 | 47 | 16 | 63 |
| 2015 4 | 27 | 6 | 33 |
| 2015 3 | 31 | 10 | 41 |
| 2015 2 | 26 | 8 | 34 |
| 2015 1 | 25 | 6 | 31 |
| 2014 12 | 16 | 7 | 23 |
| 2014 11 | 25 | 7 | 32 |
| 2014 10 | 35 | 7 | 42 |
| 2014 9 | 34 | 25 | 59 |
Mostrar todo
